Document is current
Any future updates will be listed below
-
Authors
Vardhana, Santosha A. http://orcid.org/0000-0002-3100-1298
Hwee, Madeline A.
Berisa, Mirela http://orcid.org/0000-0001-7347-9823
Wells, Daniel K.
Yost, Kathryn E.
King, Bryan http://orcid.org/0000-0003-1203-784X
Smith, Melody http://orcid.org/0000-0002-2702-0381
Herrera, Pamela S.
Chang, Howard Y. http://orcid.org/0000-0002-9459-4393
Satpathy, Ansuman T. http://orcid.org/0000-0002-5167-537X
van den Brink, Marcel R. M.
Cross, Justin R.
Thompson, Craig B. http://orcid.org/0000-0003-3580-2751
- License Information
-
More Information
Article History
Received: 12 February 2020
Accepted: 2 June 2020
First Online: 13 July 2020
Competing interests
: C.B.T. is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He is also a former member of the Board of Directors and a stockholder of Merck and Charles River Laboratories. S.A.V. has received honoraria from Agios Pharmaceuticals and Rheos Pharmaceuticals, is an advisor for Immunai and has consulted for ADC Therapeutics. A.T.S. and D.K.W. are scientific founders and equity holders of, and receive consulting fees from, Immunai. A.T.S. received funding support from 10x Genomics and Arsenal Biosciences. K.E.Y. is an advisor for Immunai. H.Y.C. is a co-founder of Accent Therapeutics and Boundless Bio and is a consultant for 10x Genomics, Arsenal Biosciences and Spring Discovery.
